Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer
Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy.
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/proc/1468262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|